UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Net income	$ 7,910	$ 5,556
Depreciation	494	536
Amortization	1,957	1,424
(Gain) loss on investments	0	(6)
Provision for (recovery of) losses on accounts receivable	10	10
Deferred income taxes	(613)	(374)
Stock-based compensation expense	54	73
Accounts receivable - trade	(140)	287
Accrued interest and other receivables	(111)	(26)
Inventories	336	(579)
Prepaid expenses and other current assets	(88)	163
Accounts payable	232	(439)
Accrued expenses	531	955
Deferred revenue	(75)	(52)
Other liability		330
Total adjustments	2,588	2,303
Net cash provided by operating activities	10,499	7,859
Capital expenditures for property and equipment	(195)	(196)
Capital expenditures for intangible assets	(1)	(8)
Purchases of investments		(500)
Proceeds from sale of investments		15,155
Net cash paid in acquisition		(41,084)
Net cash provided by (used in) investing activities	(197)	(26,633)
Proceeds from issuance of common stock - options	1,185	442
Common stock purchased and retired
Tax benefit attributable to exercise of stock options	99	30
Proceeds from notes payable		26,934
Repayments of notes payable	(7,174)	(3,682)
Payment of dividends	(1,762)	(1,705)
Net cash provided by (used in) financing activities	(7,652)	22,019
Effect of exchange rate changes on cash	103	(23)
NET INCREASE (DECREASE) IN CASH	2,754	3,222
CASH AT BEGINNING OF PERIOD	6,534	3,818
CASH AT END OF PERIOD	9,288	7,040
Cash paid during the period for income taxes	2,621	2,015
Cash paid during the period for interest	$ 516	$ 636